Elekta Valuation
Is EKTA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EKTA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EKTA B (SEK68.55) is trading below our estimate of fair value (SEK128.15)
Significantly Below Fair Value: EKTA B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EKTA B?
Other financial metrics that can be useful for relative valuation.
What is EKTA B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 26.19b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.7x |
Enterprise Value/EBITDA | 13.2x |
PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does EKTA B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 49.1x | ||
ARJO B Arjo | 23.1x | 23.7% | SEK 11.8b |
GETI B Getinge | 23.1x | 12.1% | SEK 59.7b |
CEVI CellaVision | 46x | 24.1% | SEK 6.7b |
ELOS B Elos Medtech | 104.3x | n/a | SEK 5.7b |
EKTA B Elekta | 23.1x | 17.8% | SEK 26.2b |
Price-To-Earnings vs Peers: EKTA B is good value based on its Price-To-Earnings Ratio (23.1x) compared to the peer average (49.1x).
Price to Earnings Ratio vs Industry
How does EKTA B's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: EKTA B is good value based on its Price-To-Earnings Ratio (23.1x) compared to the European Medical Equipment industry average (29.3x).
Price to Earnings Ratio vs Fair Ratio
What is EKTA B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 23.1x |
Fair PE Ratio | 24.8x |
Price-To-Earnings vs Fair Ratio: EKTA B is good value based on its Price-To-Earnings Ratio (23.1x) compared to the estimated Fair Price-To-Earnings Ratio (24.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 68.55 | SEK 76.21 +11.2% | 23.8% | SEK 127.00 | SEK 57.00 | n/a | 14 |
Sep ’25 | SEK 70.10 | SEK 76.69 +9.4% | 24.7% | SEK 127.00 | SEK 57.00 | n/a | 13 |
Aug ’25 | SEK 66.40 | SEK 76.31 +14.9% | 24.9% | SEK 127.00 | SEK 57.00 | n/a | 13 |
Jul ’25 | SEK 65.90 | SEK 76.38 +15.9% | 24.7% | SEK 127.00 | SEK 57.00 | n/a | 13 |
Jun ’25 | SEK 86.15 | SEK 84.08 -2.4% | 24.4% | SEK 127.00 | SEK 57.00 | n/a | 12 |
May ’25 | SEK 79.20 | SEK 83.42 +5.3% | 24.5% | SEK 127.00 | SEK 57.00 | n/a | 12 |
Apr ’25 | SEK 80.70 | SEK 86.00 +6.6% | 23.7% | SEK 127.00 | SEK 57.00 | n/a | 12 |
Mar ’25 | SEK 77.84 | SEK 86.33 +10.9% | 23.4% | SEK 127.00 | SEK 57.00 | n/a | 12 |
Feb ’25 | SEK 78.54 | SEK 86.67 +10.3% | 23.4% | SEK 127.00 | SEK 57.00 | n/a | 12 |
Jan ’25 | SEK 82.32 | SEK 84.73 +2.9% | 23.3% | SEK 127.00 | SEK 57.00 | n/a | 11 |
Dec ’24 | SEK 82.08 | SEK 84.91 +3.4% | 23.7% | SEK 127.00 | SEK 57.00 | n/a | 11 |
Nov ’24 | SEK 75.82 | SEK 82.00 +8.2% | 26.2% | SEK 127.00 | SEK 53.00 | n/a | 11 |
Oct ’24 | SEK 74.42 | SEK 83.30 +11.9% | 26.6% | SEK 127.00 | SEK 53.00 | n/a | 10 |
Sep ’24 | SEK 77.62 | SEK 83.30 +7.3% | 26.6% | SEK 127.00 | SEK 53.00 | SEK 70.10 | 10 |
Aug ’24 | SEK 85.18 | SEK 83.20 -2.3% | 26.2% | SEK 127.00 | SEK 57.00 | SEK 66.40 | 10 |
Jul ’24 | SEK 83.34 | SEK 85.50 +2.6% | 26.0% | SEK 127.00 | SEK 57.00 | SEK 65.90 | 10 |
Jun ’24 | SEK 81.62 | SEK 83.40 +2.2% | 25.5% | SEK 127.00 | SEK 57.00 | SEK 86.15 | 10 |
May ’24 | SEK 86.06 | SEK 81.22 -5.6% | 28.3% | SEK 127.00 | SEK 57.00 | SEK 79.20 | 10 |
Apr ’24 | SEK 79.08 | SEK 81.22 +2.7% | 28.3% | SEK 127.00 | SEK 57.00 | SEK 80.70 | 10 |
Mar ’24 | SEK 80.62 | SEK 77.91 -3.4% | 28.7% | SEK 127.00 | SEK 57.00 | SEK 77.84 | 9 |
Feb ’24 | SEK 76.46 | SEK 73.67 -3.7% | 31.5% | SEK 127.00 | SEK 52.00 | SEK 78.54 | 9 |
Jan ’24 | SEK 62.80 | SEK 70.44 +12.2% | 31.8% | SEK 127.00 | SEK 52.00 | SEK 82.32 | 9 |
Dec ’23 | SEK 63.18 | SEK 72.75 +15.1% | 32.5% | SEK 127.00 | SEK 52.00 | SEK 82.08 | 8 |
Nov ’23 | SEK 57.50 | SEK 76.13 +32.4% | 29.6% | SEK 127.00 | SEK 55.00 | SEK 75.82 | 8 |
Oct ’23 | SEK 56.86 | SEK 80.43 +41.5% | 27.1% | SEK 127.00 | SEK 59.00 | SEK 74.42 | 7 |
Sep ’23 | SEK 59.00 | SEK 80.43 +36.3% | 27.1% | SEK 127.00 | SEK 59.00 | SEK 77.62 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.